Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Mortality 50% Improvement Relative Risk Death/hospitalization 43% primary c19early.org/pl Schwartz et al. Paxlovid for COVID-19 EARLY TREATMENT Favors paxlovid Favors control
Real-world effectiveness of nirmatrelvir/ritonavir use for COVID-19: A population-based cohort study in Ontario, Canada
Schwartz et al., medRxiv, doi:10.1101/2022.11.03.22281881 (Preprint)
5 Nov 2022    Source   PDF   Share   Tweet
Retrospective 177,545 patients in Canada, 8,876 treated with paxlovid, showing lower mortality and hospitalization with treatment, and declining efficacy over the two time periods analyzed.
risk of death, 50.2% lower, RR 0.50, p < 0.001, treatment 142 of 8,876 (1.6%), control 5,566 of 168,669 (3.3%), NNT 59, odds ratio converted to relative risk, propensity score weighting.
risk of death/hospitalization, 43.1% lower, RR 0.57, p < 0.001, treatment 186 of 8,876 (2.1%), control 6,241 of 168,669 (3.7%), NNT 62, odds ratio converted to relative risk, propensity score weighting, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Schwartz et al., 5 Nov 2022, retrospective, Canada, preprint, mean age 74.0, 10 authors, study period 4 April, 2022 - 31 August, 2022.
Contact: kevin.schwartz@oahpp.ca.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperPaxlovidAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit